NEW YORK – Proteomics sample prep firm PreOmics announced on Tuesday that it has closed a €13.5 million ($15.3 million) Series B funding round.
The company said that it plans to use the funds to increase investments in R&D as well as sales and marketing of its sample prep technologies.
Bruker was the sole investor in the round. In a secondary transaction, the mass spec vendor bought out existing PreOmics investors including High-Tech Gründerfonds and Think.Health Ventures and is now a majority investor in the company.
PreOmics said it expected that its sample prep technologies, including its BeatBox tissue and cell homogenization device, in combination with Bruker's timsTOF mass spec platform would drive uptake of both systems among academic, pharma, and clinical researchers by providing a more complete and automated proteomics workflow.
"Our novel BeatBox technology is seamlessly compatible with PreOmics’ proteomic sample preparation technologies and in combination with the timsTOF Pro provides end-to-end workflows for processing of large tissue biobanks," Nils Kulak, cofounder and managing director of PreOmics, said in a statement. "Furthermore, we aim to develop integrated and automated BeatBox-based workflow solutions for every experience level and throughput need, while providing highest performance levels for unbiased, deep and comprehensive proteomics research."
"We are very pleased to invest in PreOmics, a leading proteomics sample preparation, automation, and consumables company, with this Series B primary financing," said Frank Laukien, president and CEO of Bruker. "By also acquiring a majority investment in PreOmics, Bruker further expands its proteomics vision to include the unique PreOmics sample preparation technologies, as well as more comprehensive, automated, robust and reproducible workflows and consumables for translational, biomarker, and biopharma proteomics research."